Nasus Pharma

Nasus Pharma EBIT per Share

The EBIT per Share of Nasus Pharma (NSRX) as of Oct 25, 2026 is -0.54 USD. In the previous year, EBIT per Share was -0.15 USD — a change of 261.58% (lower).

EBIT per Share

-0.54USD

YoY

261.58%

Last updated:

EBIT per Share of Nasus Pharma is 2025 -0.54 USD. EBIT per Share of Nasus Pharma was 2024 -0.15 USD. It decreases by 261.58% lower compared to the previous year.

The Nasus Pharma EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-0.17 USD
Jan 1, 2024
-0.15 USD
Jan 1, 2025
-0.54 USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
0.00 USD
Jan 1, 2028 (e)
-0.45 USD
Jan 1, 2029 (e)
0.26 USD
Jan 1, 2030 (e)
1.31 USD
The Nasus Pharma EBIT per Share history
YEAREBIT per ShareYoY
est1.31USD+410.15%
est0.26USD-156.99%
est-0.45USD—
est0.00USD—
est0.00USD-100.00%
-0.54USD+261.58%
-0.15USD-9.64%
-0.17USD-9.74%
-0.18USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nasus Pharma Stock analysis

What does Nasus Pharma do? Nasus Pharma Ltd is an Israel-based pharmaceutical company specializing in microsphere technology for intranasal powder-based drug delivery systems. The firm manufactures pharmaceutical preparations designed for rapid, non-invasive administration of medications targeting conditions like anaphylaxis and opioid overdose. Their products focus on fast absorption, ease of use, and effectiveness in emergency scenarios, enabling caregivers, non-professionals, and medical professionals to administer life-saving treatments without specialized training. Nasus Pharma Ltd's formulations aim to improve access to critical medications by simplifying administration in urgent situations. The company's primary products are intranasal powder-based drug delivery systems utilizing microsphere technology. These systems are tailored for conditions requiring immediate intervention, such as anaphylaxis and opioid overdose. The firm targets medical doctors, emergency nurses, and caregivers as key buyers, emphasizing the products' role in critical care settings where speed and simplicity are essential. Nasus Pharma Ltd positions itself as a provider of accessible emergency treatments that bridge gaps in traditional medical administration. Nasus Pharma Ltd's business model centers on developing and commercializing pharmaceutical preparations that leverage microsphere technology for intranasal delivery. The company focuses on creating solutions for life-saving treatments that can be administered by non-specialists, thereby expanding the reach of critical medications. By addressing the need for rapid, non-invasive drug delivery in emergencies, Nasus Pharma Ltd caters to healthcare providers and emergency responders who require reliable, easy-to-use products during critical incidents. Nasus Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nasus Pharma stock

EBIT per Share of Nasus Pharma is -0.54 USD in 2025.

EBIT per Share of Nasus Pharma changed from -0.15 USD to -0.54 USD, representing a 261.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Nasus Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Nasus Pharma

All Key Metrics — Nasus Pharma